primary packaging for biopharmaceuticals: challenges & options · glass packaging is still the...

25
© SCHOTT AG Horst Koller, SCHOTT Schweiz AG Primary Packaging For Biopharmaceuticals: Challenges & Options MIBio 2014; Cambridge, UK; 30 Sep 2014

Upload: others

Post on 21-Jul-2020

1 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

© SCHOTT AGHorst Koller, SCHOTT Schweiz AG

Primary Packaging For Biopharmaceuticals: Challenges & OptionsMIBio 2014; Cambridge, UK; 30 Sep 2014

Page 2: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

Agenda

© SCHOTT AG

1

Horst Koller, SCHOTT Schweiz AG

1. Glass and Plastics as Packaging Materials

2. Introduction to Extractable and Leachable (E&L)

3. Challenges of Primary Packaging

4. Options for Optimization

5. Summary

MIBio 2014; Cambridge, UK; 30 Sep 2014

Page 3: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Glass and Plastics as Packaging Materials

2

Horst Koller, SCHOTT Schweiz AG

MIBio 2014; Cambridge, UK; 30 Sep 2014

Page 4: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Chemical Composition of Glass

3

Horst Koller, SCHOTT Schweiz AG

Quarz crystalMP >2000°C

Quarz glassMP ~1700°C

Mixture of crystalline oxides, carbonates, etc. Glass is a “frozen super cooled liquid” Glass is an inorganic melt, cooled down and solidified without

crystallization. Considered solid below ~500ºC, without defined melting point

because of its amorphous structure. Composed of:

Network former : SiO2 (SiO44-)

Network modifiers to lower melting point - Na2O, B2O3,PbO

Stabilizers to improve durability - CaO, Al2O3

Colorants as needed - Fe2O3 - TiO2

MIBio 2014; Cambridge, UK; 30 Sep 2014

Page 5: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Chemical Composition of Glass

4

Potential E & L from glass: Silicon Oxygen Sodium, Potassium Aluminum Boron Calcium, Magnesium, Barium

FIOLAX®

clearFIOLAX®

amberBORO-8330TM

ILLAX® AR-GLAS®

Si Si Si Si Si

O O O O O

Na Na Na Na Na

Al Al Al Al Al

B B B B B

Ca Ca K Ca Ca

Fe K K

Ti Mn Mg

K Fe Ba

Ba Ba

Hydrolytic Resistance Class

I I I III III

MIBio 2014; Cambridge, UK; 30 Sep 2014

Horst Koller, SCHOTT Schweiz AG

Page 6: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Chemical Composition of Plastics

Horst Koller, SCHOTT Schweiz AG

C CH

HH

H

C CCl

HH

H

C CF

FF

F

C CCH3

HH

H

COC: Cyclic Olefin Copolymer

COP: Cyclic Olefin Polymers

PE: Poly-Ethylene PE: Poly-TetraFluor-Ethylene

PP: Poly-Propylene PVC: Poly-Vinyl-Chlorid

Polymerization of Monomers; cyclic and / or linear Amorphous and non-amorphous structures Different glass transition temperatures Composed of:

Antioxidants Colorants UV Stabilizers Catalysts Slip Additives

MIBio 2014; Cambridge, UK; 30 Sep 2014 5

Page 7: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Chemical Composition of Plastics

6MIBio 2014; Cambridge, UK; 30 Sep 2014

Horst Koller, SCHOTT Schweiz AG

Potential E & L from plastics: Lubricants Monomers Oligomers Degradation products Solvents

Pentaerythritol Tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate) [Ix1010]

Oleamide

Ultramarine Blue

Page 8: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

Agenda

© SCHOTT AG

7

Horst Koller, SCHOTT Schweiz AG

1. Glass and Plastics as Packaging Materials

2. Introduction to Extractable and Leachable (E&L)

3. Challenges of Primary Packaging

4. Options for Optimization

5. Summary

MIBio 2014; Cambridge, UK; 30 Sep 2014

Page 9: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Introduction to Extractable and Leachable (E&L)

8

Extractables:Components of a certain packaging material that are released during a certain stress test procedure(e.g. aggressive solvents, exaggerated conditions of time and temperature)

Extractables are determined by exposing components or systems to conditions that are more severethan normally found in a biopharmaceutical process, typically using a variety of solvents at hightemperatures. The goal of an extractable study is to identify as many compounds as possible that havethe potential to become leachables.

MIBio 2014; Cambridge, UK; 30 Sep 2014

Horst Koller, SCHOTT Schweiz AG

Leachables:Components of the container closure system that are migrating into the drug formulation during usualproduction process and storage

Up to now it was believed that leachables are a subset of extractables. Nowadays it has become moreclearly that there is a possibility of the occurrence of leachables that are not detected by the usualextractables screenings e.g. because they form under special and different conditions between thedrug formulation and some material components. It is thus not recommended to rely solely onExtractables data.

Page 10: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Introduction to Extractable and Leachable (E&L)

Leachables

Extractables Extractables

Leachables

THEORY PRACTICE

Closing the GAP

Leachables

MIBio 2014; Cambridge, UK; 30 Sep 2014 9

Horst Koller, SCHOTT Schweiz AG

Page 11: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

Agenda

© SCHOTT AGHorst Koller, SCHOTT Schweiz AG

1. Glass and Plastics as Packaging Materials

2. Introduction to Extractable and Leachable (E&L)

3. Challenges of Primary Packaging

4. Options for Optimization

5. Summary

MIBio 2014; Cambridge, UK; 30 Sep 2014 10

Page 12: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Challenges of Primary Packaging (E&L)

The occurence of potential extractables and leachables fromthe container material are influenced by multiple factors: Glass Composition / Plastic Composition Converting Process: Hot Forming / Injection Molding Container Size / Volume Ratio Container Lubrification: Silicone Oil in Syringes / Vials Drug Product: pH-Value, Complexing Agents, Buffers, Solvents Storage Conditions

Horst Koller, SCHOTT Schweiz AG

Figure 1 shows the difference in extractables concentration depending on thetemperature during converting. 2ml ampoules from Lot A were converted withhigh temperature and Lot B with low temperature. An extraction according to ISO4802-2 showed higher values for Sodium and Aluminum in case of Lot B.

MIBio 2014; Cambridge, UK; 30 Sep 2014 11

Figure 1

Page 13: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Challenges of Primary Packaging (E&L)

Extractable Metal ions from the hot forming process can trigger: Precipitation Aggregation Degradation Inactivation of active sites

Horst Koller, SCHOTT Schweiz AG

Tungsten-OxideChannel Forming of Staked Needle Syringe with Tungsten Pin

MIBio 2014; Cambridge, UK; 30 Sep 2014 12

Page 14: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Challenges of Primary Packaging (Delamination)

Delamination is a glass wall morphology phenomena: Can be seen as flakes (Fig 1a / 1b) It is most pronounced in the transition zone between the wall and bottom (Fig 2) It is linked with a porous reaction layer (Fig 3)

Horst Koller, SCHOTT Schweiz AG

Figure 2

Figure 1a

Figure 1b Figure 3

MIBio 2014; Cambridge, UK; 30 Sep 2014 13

Page 15: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Challenges of Primary Packaging (Permeation)

3ml Glass Syringe vs. 3ml Plastic Syringe

Horst Koller, SCHOTT Schweiz AG

Syringe System Glass vs. Polymer BIF = 9,6 related to H2O Permeation

MIBio 2014; Cambridge, UK; 30 Sep 2014 14

H2O Loss during storage at 40°C / ambient r.H.

Page 16: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

Agenda

© SCHOTT AGHorst Koller, SCHOTT Schweiz AG

1. Glass and Plastics as Packaging Materials

2. Introduction to Extractable and Leachable (E&L)

3. Challenges of Primary Packaging

4. Options for Optimization

5. Summary

MIBio 2014; Cambridge, UK; 30 Sep 2014 15

Page 17: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Options for Optimizations

Functional Coatings to optimize Surface properties

Horst Koller, SCHOTT Schweiz AG

SCHOTT TopYield™ vialsSCHOTT Vials Delamination Controlled SCHOTT TopLyo® vials

MIBio 2014; Cambridge, UK; 30 Sep 2014 16

Page 18: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Options for Optimizations

Barrier Coatings to optimize Barrier Improvement factor (BIF)

Horst Koller, SCHOTT Schweiz AG

extractable glassnon coated

glasscoated

BIF

Sodium 3.5 <0.01 350

Calcium 1.1 <0.05 22

Bor 3.5 <0.1 35

Silicium 5.0 <0.3 15

Aluminum 2.3 <0.05 45

Leached Ions in µg/ml by AAS; after autoclaving at 1h/121°C, filled with 0,4m HCL

SCHOTT Type I Plus® vials

MIBio 2014; Cambridge, UK; 30 Sep 2014 17

Page 19: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Options for Optimizations

Barrier Coatings to optimize Oxygen (O2) Barrier

Horst Koller, SCHOTT Schweiz AG

MIBio 2014; Cambridge, UK; 30 Sep 2014 18

Page 20: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Options for Optimizations

Barrier Improvements through Molding Technologies

Horst Koller, SCHOTT Schweiz AG

Multilayer System

0

0,1

0,2

0,3

0,4

0,5

Comparison Permeation Coefficient

COC no barrier

COC barrier A

COC barrier B

COC barrier C

COC barrier D

Barrier BIF

A 2.7

B 6.5

C 6.5

D 3.2

Reference : TechniCAL Brochure Co-Injection; Windsor Polymertechnology/ Germany

MIBio 2014; Cambridge, UK; 30 Sep 2014 19

Page 21: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Advantages / Disadvantages of Material

Horst Koller, SCHOTT Schweiz AG

Vs.

Polymer Vs. Glass

Feature Polymer Glass

Absence of Heavy Metal‘s better

Breakage Resistance better

Design Space / Customizing / Tolerances better

Discoloration by radiation better

Handling in Standard Filling Lines better

Temperature Resistance better

MIBio 2014; Cambridge, UK; 30 Sep 2014 20

Page 22: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Advantages / Disadvantages of Material

Horst Koller, SCHOTT Schweiz AG

Polymer Vs. Glass

Feature Polymer Glass

Low E & L Profile better

„long term“ experience better

Multiple Supply Source better

Permeability (gases) better

Delamination better

Sterilization Possibilities better

MIBio 2014; Cambridge, UK; 30 Sep 2014 21

Vs.

Page 23: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

Agenda

© SCHOTT AGHorst Koller, SCHOTT Schweiz AG

1. Glass and Plastics as Packaging Materials

2. Introduction to Extractable and Leachable (E&L)

3. Challenges of Primary Packaging

4. Options for Optimization

5. Summary

MIBio 2014; Cambridge, UK; 30 Sep 2014 22

Page 24: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

Pharmaceutical Packaging

© SCHOTT AG

Summary

Glass packaging is still the `state of the art` packaging for biopharmaceuticals

Container materials are always multi-ingredient compositions

Leachable is time depending (Mind the gap)

Surface optimization is possible but often costly

Each and all container materials have their individual advantages and

disadvantages

There is no “one container fits all type and surface”

MIBio 2014; Cambridge, UK; 30 Sep 2014 23

Horst Koller, SCHOTT Schweiz AG

Page 25: Primary Packaging For Biopharmaceuticals: Challenges & Options · Glass packaging is still the `state of the art` packaging for biopharmaceuticals Container materials are always multi-ingredient

© SCHOTT AG

Thank you for your attention!Questions?

Horst Koller, SCHOTT Schweiz AG